- This topic has 2 replies, 2 voices, and was last updated 1 month ago by
.
-
Posts
-
A new utuc study — not ready for prime time and a small cohort but promising research.
Hi Lisa,
Thanks for the post! I have been digging down another rabbit hole lately. Even though these holes seem bottomless, I wanted to stop digging for a moment and share what I have picked up so far. My writing was a mess as usual, so I tried Google AI summarize my writing.
The Accessibility Challenge
The urine-based biomarker test utLIFE—used for detecting bladder cancer (UC) and upper tract urothelial carcinoma (UTUC)—is either currently available or very close to it. However, accessibility is a major hurdle for us. It was developed by Acornmed Biotechnology, a Chinese startup founded in 2018. Because its co-founder (who holds a bioinformatics PhD from Paris) is a liquid biopsy pioneer in China, the test is primarily accessible there for now.
First-Generation vs. Next-Generation Tools
1. Acorn UI-SEEK (First Gen)
· Technology: PCR-based urine test.
· Biomarkers: Detects abnormalities in TERT promoter and FGFR3 mutations, alongside ONECUT2 and VIM methylation.
· TERT promoter mutations immortalize cells.
· FGFR3 mutations cause continuous cell division.
· ONECUT2 methylation/silencing disables DNA double-strand break repairs.
· VIM methylation/silencing weakens cell structure.
· Performance: Its accuracy exceeds traditional urine cytology and UroVysion (FISH). It is highly decentralized; any small lab with a PCR tester can run it. It even helped reduce the need for in-person cystoscopies during China’s COVID-19 lockdowns.
2. utLIFE (Advanced Gen)
utLIFE is a much more advanced diagnostic workflow that utilizes a Support Vector Machine (SVM) machine learning model to analyze three distinct components:
· Targeted Gene Sequencing: Uses urine cell-free DNA to analyze 150 bladder cancer-associated genes (including TERT, TP53, ERBB2, ERCC, and FGFR3), which were originally identified from tissue samples of 85 bladder cancer patients.
· Genome-Wide Copy Number Variation (CNV): Healthy cells contain exactly two copies of each DNA segment. Cancer cells often undergo chromosomal instability (CIN), leaving segments with multiple copies or just one. utLIFE utilizes the non-broken cells in urine to calculate a CNV value; a higher score indicates higher chromosomal instability.
· The SVM AI Model: This algorithm was trained on data from 85 Chinese bladder cancer patients and 67 healthy controls. Crucially, it was validated using the TCGA-BLCA dataset (published by a US-based collaborative consortium in 2014 with 131 cases, and expanded in 2017 to 412 cases). Because the TCGA cohort is predominantly North American, it suggests utLIFE’s algorithm is globally applicable, not just limited to Asian populations.
Clinical Evidence & Accuracy
· Bladder Cancer / Residual Disease (2023 Study): For detecting primary tumors (e.g., evaluating hematuria) and monitoring Minimal Residual Disease (MRD) after a TURBT, utLIFE-UC achieved a remarkable 92.8% sensitivity and 96.0% specificity, vastly outperforming UI-SEEK.
· UTUC Early Diagnosis (2024 Study): While the initial 2023 study only included 11 UTUC patients, a larger multi-center study published in Cancer Medicine (September 2024) by Peking University and Acornmed evaluated 93 UTUC patients. The results were stark:
· Overall Sensitivity: utLIFE reached 95%, compared to just 26% for cytology and 37% for FISH.
· Low-Grade (G1/G2) Tumors: utLIFE maintained 100% sensitivity, whereas cytology dropped to 16.7% and FISH sat at 37%.
· High-Grade (HG) Tumors: utLIFE achieved 92.3% sensitivity, compared to 30.8% for cytology and 76.9% for FISH.
· UTUC Recurrence Monitoring (MRD): The same team used utLIFE to track bladder recurrence 3 to 6 months after a radical nephroureterectomy (RNU)—which is the exact article you posted! At the 3-to-6-month mark, utLIFE predicted Recurrence-Free Survival (RFS) with 83.3% sensitivity, compared to only 16.7% for cytology and cystoscopy. Essentially, it can catch a recurrence 3 to 6 months before a tumor becomes visible on a cystoscopy.
Clinical Implications: The “Pre-Emptive” Treatment Idea
Catching a recurrence before a visible tumor forms is highly valuable because treatments like BCG are much more effective at a microscopic stage. This mirrors a common strategy used in the US with blood-based liquid biopsies:
· The Blood Analogy (Signatera): Consider a patient who undergoes a radical cystectomy for MIBC but doesn’t qualify for adjuvant Nivolumab because they aren’t deemed ‘high risk’ for metastasis. Doctors will often put them on surveillance using Signatera (a blood-based ctDNA test). The moment Signatera detects matching cancer DNA fragments in the blood, the doctor immediately initiates Nivolumab immunotherapy—treating the cancer before it can be seen on a scan.
· The utLIFE Advantage: While Signatera is ’tissue-informed’ (meaning it requires a piece of the patient’s actual tumor tissue to design a custom test first), utLIFE is a fixed panel. It checks the urine against a pre-built model trained on 150 genes and validated by TCGA data. This makes utLIFE significantly less expensive.
What This Means for Us
We urgently need tools like utLIFE for UTUC to allow for early intervention and to reduce bladder recurrence. Right now, a single instillation of chemotherapy is recommended immediately after an RNU to kill stray cancer cells, but it doesn’t always work. The standard remaining surveillance protocol relies heavily on cystoscopy and cytology, which this clinical data proves are far less effective.
Acornmed’s website notes that utLIFE-UC was granted an FDA Breakthrough Device Designation in September 2023. However, since Acornmed is still a relatively small biotech firm operating out of China, it remains uncertain when or how this designation will translate into true clinical accessibility for Canadian patients.
Let me know what you think!
References
1. Clinical Utility of Urine DNA for Noninvasive Detection and Minimal Residual Disease Monitoring in Urothelial Carcinoma Sep 2022
2. A Novel Urine DNA Predictor for Noninvasive Early Diagnosis and Monitoring Minimal Residual Disease of Upper Tract Urothelial Carcinoma 2024
- You must be logged in to reply to this topic.
